Antibiotic Therapy in Neonatal and Pediatric Septic Shock
- First Online:
- Cite this article as:
- Aneja, R.K., Varughese-Aneja, R., Vetterly, C.G. et al. Curr Infect Dis Rep (2011) 13: 433. doi:10.1007/s11908-011-0197-5
- 403 Downloads
Severe sepsis accounts for nearly 4,500 deaths (mortality rate 10%), and is responsible for nearly $2 billion annual healthcare expenditure in the United States. Early and speedy treatment of critically ill septic patients can halt or reduce the likelihood of physiologic progression to multi-system organ failure. A cornerstone of this therapeutic strategy is antibiotic administration. In this review, we discuss the empirical treatment strategies for the treatment of early and late neonatal sepsis, along with pediatric sepsis. Furthermore, we discuss the rationale that underlies the adoption of such treatment strategies. The present article also discusses the emergence of multi-drug organisms as the causative agents for sepsis, i.e. methicillin-resistant Staphylococcus aureus (MRSA), resistant enterococci and Klebsiella pneumoniae carbapenemases (KPC).